Vivoryon Reports Nine-Month Loss, Regains China Rights
The Halle-based drug developer posted a net loss of EUR 4.8 million and no revenue for the nine months ended September 30, 2026.
Updated on Nov. 5, 2026 in Corporate Finance
Vivoryon Therapeutics N.V. reported financial results for the nine months ended September 30, 2026, recording zero revenue and a net loss of EUR 4.8 million. The company also signed a Termination Agreement with Simcere Pharmaceutical Group that returns development and commercial rights for varoglutamstat in Greater China to Vivoryon.
Why it matters
The return of regional rights gives Vivoryon control over varoglutamstat in Greater China while its cash position is limited. The company's existing cash is expected to last only into the second half of December 2026.
The interim results show R&D spending fell EUR 1.4 million year over year while cash dropped from EUR 5.6 million to EUR 1.7 million between December 2025 and September 2026. Whether a Phase 2b study can proceed without new funding or a partnership has not been determined.
The players
Vivoryon Therapeutics N.V.
A Halle (Saale)-based clinical-stage biopharmaceutical company developing treatments for kidney disease and Alzheimer's disease, including the candidate varoglutamstat.
Simcere Pharmaceutical Group
A China-based pharmaceutical company that held regional development and commercial rights to varoglutamstat in Greater China before agreeing to return them.
The details
Simcere will be eligible for certain payments upon achieving specified regulatory milestones in Greater China, and no cash payment is due from Vivoryon upon termination. The R&D decline was largely driven by lower kidney-related clinical development and analysis costs of EUR 1.0 million, while G&A fell on lower non-cash share-based personnel costs and cost-saving measures.
Timeline
September 2026: Annual General Meeting held in Amsterdam, with shareholders approving all agenda items.
September 30, 2026: Nine-month reporting period closed with EUR 1.7 million in cash.
Second half of December 2026: Projected end of current cash runway.
Market Dynamics
The rights return follows Vivoryon's Phase 2 VIVIAD and VIVA-MIND studies, which showed statistically significant eGFR improvement versus placebo in kidney disease. The move reshapes the company's financing options as it seeks to advance varoglutamstat without a regional licensing partner in Greater China.
Investors holding Vivoryon shares face a company with only EUR 1.7 million in cash and a runway ending in late December 2026. Continued operating losses are expected for the foreseeable future, so any new equity raise or partnership could dilute existing holdings.
The takeaway
Cash runway, not clinical promise, is the near-term constraint for Vivoryon, and the next funding or partnership announcement will likely determine the company's direction.
What happens next
Vivoryon's current cash is projected to last into the second half of December 2026, a date by which the company must secure new funding or a partnership to continue operations.
Further reading
Track more deals in the Corporate Finance section.
